SCHEMBL4434089

SCHEMBL4434089

CC(C)(C)OC(=O)ON1CCCC1

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.39
USP2 O75604 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
CTSK P43235 2/20 0.37
PREP P48147 2/20 0.35
EPHX1 P07099 1/20 0.33
ELANE P08246 1/20 0.32
CHRM2 P08172 1/20 0.32
CHRM1 P11229 1/20 0.32
CHRM3 P20309 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.31
DGAT1 O75907 1/20 0.31
CTSL P07711 1/20 0.31
CTSB P07858 1/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
HSD17B10 Q99714 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2373613 0.98 HPGD (0.41) HPGDUSP2SMN1; SMN2CTSKPREP
SCHEMBL16673827 0.84 CA2 (0.32) USP2SMN1; SMN2CTSK
SCHEMBL3817248 0.83 USP2 (0.35) HPGDUSP2SMN1; SMN2CTSKELANE
SCHEMBL689398 0.82 CTSK (0.30) USP2SMN1; SMN2CTSK
SCHEMBL106664 0.82 USP2 (0.34) HPGDUSP2SMN1; SMN2CTSKELANE
SCHEMBL689237 0.81
SCHEMBL212033 0.80 CHRM2 (0.42) HPGDUSP2SMN1; SMN2CTSKPREP
SCHEMBL2564447 0.80 USP2 (0.33) USP2SMN1; SMN2CTSKELANE
SCHEMBL4064598 0.80 USP2 (0.33) HPGDUSP2SMN1; SMN2CTSKEPHX1
SCHEMBL8681208 0.80 FKBP1A (0.31) CTSKMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1737823-A2 NOVEL ALKYNE COMPOUNDS WITH AN MCH-ANTAGONISTIC ACTION AND MEDICAMENTS COMPRISING SAID COMPOUNDS Boehringer Ingelheim International GmbH (DE) 2007-01-03 EP claimed
WO-2005103002-A2 NOVEL ALKYNE COMPOUNDS WITH AN MCH-ANTAGONISTIC ACTION AND MEDICAMENTS COMPRISING SAID COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-11-03 WO claimed
CN-110291082-A INHIBITORS OF NHE-MEDIATED ANTIPORT 阿德利克斯股份有限公司 2019-09-27 CN disclosed
CN-104334546-B Novel ring-substituted N-pyridyl amides as kinase inhibitors 诺华股份有限公司 2017-05-03 CN disclosed
EP-2132193-A1 SUBSTITUTED PYRROLIDINE AMIDES, THE PRODUCTION THEREOF, AND THE USE THEREOF AS MEDICATIONS Boehringer Ingelheim International GmbH (DE) 2009-12-16 EP disclosed
WO-2008116881-A1 SUBSTITUTED PYRROLIDINE AMIDES, THE PRODUCTION THEREOF, AND THE USE THEREOF AS MEDICATIONS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-10-02 WO disclosed
CN-1882572-A Quinazoline derivatives as antitumor agents ASTRAZENECA AB (SE) 2006-12-20 CN disclosed
CN-1703221-A 2-alkyl- (2-amino-3-aryl-propionyl) -piperazine derivatives and related compounds as melanocortin receptor ligands for the treatment of obesity PROCTER & GAMBLE (US) 2005-11-30 CN disclosed
CN-1543461-A Melanocortin receptor ligands 2004-11-03 CN disclosed
US-5843983-A Diphenylethane compounds containing a saturated heterocyclic group, their preparation, and their therapeutic use SANKYO COMPANY, LIMITED (JP) 1998-12-01 US disclosed
EP-0844000-A1 Use of alpha, omega-diarylalkane derivatives in the treatment and prevention of psychosis SANKYO COMPANY LIMITED (JP) 1998-05-27 EP disclosed
EP-0790235-A1 Diaryl alkane derivatives containing an alicyclic group, their preparation and their therapeutic and prophylactic uses SANKYO COMPANY LIMITED (JP) 1997-08-20 EP disclosed
US-5556864-A TREATMENT OF CIRCULATORY DISEASES AND PSYCHOSIS SANKYO COMPANY, LIMITED (JP) 1996-09-17 US disclosed
EP-0600717-A1 Phenoxyalkylamines, -pyrrolidines and -piperidines for the treatment and prevention of circulatory diseases and psychosis SANKYO COMPANY LIMITED (JP) 1994-06-08 EP disclosed